株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心筋梗塞:パイプライン分析

Myocardial Infarction - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 229746
出版日 ページ情報 英文 307 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.10円で換算しております。
Back to Top
心筋梗塞:パイプライン分析 Myocardial Infarction - Pipeline Review, H1 2017
出版日: 2017年03月31日 ページ情報: 英文 307 Pages
概要

心筋梗塞(または心臓虚血)は、心筋への血流・酸素供給が不足した際に生じます。主な徴候・症状として、胸痛(特に人体の左側(狭心症))をはじめ、頚部・顎の痛み、肩・腕の痛み、冷や汗、息切れ、吐き気・嘔吐などが挙げられます。また、冠動脈疾患(アテローム硬化症)や血栓、冠血管攣縮、その他の重病が原因で発症することがあります。発症リスクの増大要因として、喫煙や糖尿病、高血圧、高コレステロール血症(高トリグリセリド血症)、運動不足、肥満、家族歴などが考えられています。

当レポートでは、世界各国での心筋梗塞治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

心筋梗塞の概要

治療薬の開発

  • 心筋梗塞向けパイプライン製品:概要
  • 心筋梗塞向けパイプライン製品:比較分析

各企業で開発中の心筋梗塞治療薬

大学/研究機関で研究中の心筋梗塞治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

心筋梗塞治療薬:開発中の製品の一覧(企業別)

心筋梗塞治療薬:研究中の製品の一覧(大学/研究機関別)

心筋梗塞治療薬の開発に従事している企業

  • Amarantus Bioscience Holdings, Inc.
  • Angion Biomedica Corp.
  • Asterias Biotherapeutics, Inc.
  • AstraZeneca Plc
  • Athersys, Inc.
  • Bayer AG
  • Bharat Biotech International Limited
  • BioCardia, Inc.
  • Biscayne Pharmaceuticals, Inc.
  • Capricor Therapeutics, Inc.
  • CellProthera
  • Celyad SA
  • Compugen Ltd.
  • CSL Limited
  • Cynata Therapeutics Limited
  • FibroGen, Inc.
  • Hemostemix Ltd
  • Human Stem Cells Institute
  • HUYA Bioscience International, LLC
  • Immune Pharmaceuticals Inc.
  • Juventas Therapeutics, Inc.
  • Laboratoires Pierre Fabre SA
  • Lee's Pharmaceutical Holdings Limited
  • LegoChem Biosciences, Inc
  • LG Life Science LTD.
  • Medestea Research & Production S.p.A.
  • Mesoblast Limited
  • miRagen Therapeutics, Inc.
  • Moderna Therapeutics, Inc.
  • MorphoSys AG
  • NeuroVive Pharmaceutical AB
  • New World Laboratories, Inc.
  • Novartis AG
  • Omeros Corporation
  • 大塚ホールディングス
  • Pfizer Inc.
  • Polyphor Ltd.
  • Primary Peptides, Inc.
  • Quantum Genomics SA
  • Quark Pharmaceuticals, Inc.
  • Recardio GmbH
  • Serodus ASA
  • Silver Creek Pharmaceuticals, Inc.
  • Stealth BioTherapeutics Inc.
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Private Limited
  • TaiGen Biotechnology Co., Ltd.
  • Targazyme, Inc.
  • The International Biotechnology Center (IBC) Generium
  • TiGenix NV
  • Vicore Pharma AB
  • XBiotech USA, Inc.
  • Yuyu Pharma, Inc.
  • Zydus Cadila Healthcare Limited

心筋梗塞:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (sacubitril + valsartan)
  • AB-002
  • ACP-01
  • Alda-1
  • アルテプラーゼ(血栓溶解薬)のバイオシミラー
  • AMRS-001
  • ANG-4011
  • 心筋梗塞向けmiR-92阻害アンチセンスRNAiオリゴヌクレオチド
  • AP-102
  • APO-1
  • balixafortide
  • リウマチ性関節炎・急性心筋梗塞・炎症性疾患向けバイオシミラー 3
  • BIS-5409
  • bococizumab
  • burixafor
  • C-21
  • C3BSGQR-3
  • C3BSGQR-4
  • CAP-1001
  • CAP-1002
  • cenderitide
  • CGEN-856S
  • CIGB-500
  • CM-1
  • Cryocell
  • CSL-112
  • CTX-101
  • cyclosporine
  • 循環器疾患向けAlpha Myosin阻害薬
  • 虚血性脳卒中・心筋梗塞向けSIRT2阻害薬
  • dutogliptin tartrate
  • elamipretide
  • 心筋梗塞向けエフリンA-1
  • F-573
  • FG-6874
  • Gemacell
  • 急性心筋梗塞向け遺伝子療法
  • HBI-3802
  • HYPER-IL-6
  • ICG-001
  • IS-20
  • JI-38
  • JVS-100
  • JVS-200
  • KR-33028
  • LC-280126
  • LWnt-3a
  • Lysimab
  • MGN-1374
  • MGN-6114
  • MIF-2
  • MIF-20
  • 心筋梗塞・アテローム性動脈硬化症向けIL-1a阻害モノクローナル抗体
  • 心筋梗塞向けマンノース受容体標的モノクローナル抗体複合体
  • MPC-150IM
  • MPC-25IC
  • Neu-2000
  • NP-202
  • NVP-019
  • NVX-308
  • NWL-53
  • 腫瘍学・心臓血管向けオリゴヌクレオチド
  • 循環器疾患・腎疾患 向けオリゴヌクレオチド
  • OMS-721
  • OPC-28326
  • 循環器疾患・代謝障害・勃起障害向けMas関連Gタンパク質共役受容体活性ペプチド
  • 糖尿病・心不全向けアペリン受容体作動ペプチド
  • PF-05285401
  • 急性心筋梗塞向けポリグラクチン 370
  • PP-001
  • 心筋梗塞・重症肢虚血向けLRP5/LRP6作動タンパク
  • ProtheraCytes
  • QGC-101
  • QPCP-1
  • RBB-001
  • 循環器疾患向け組換タンパク
  • 心筋梗塞向け組換タンパク質
  • 心筋梗塞向けIGF-1R作動組換タンパク
  • 組換プロウロキナーゼ
  • remestemcel-L
  • rivaroxaban
  • 心筋梗塞向けRNAiオリゴヌクレオチド
  • salicylamine
  • SER-130
  • 心筋梗塞向け小分子
  • 再かん流傷害・心臓まひ向け小分子
  • CAHD・脳卒中向け血液因子XIa阻害剤
  • 心筋梗塞・炎症性疾患向け小分子
  • 喘息・心筋梗塞向けアデノシンA2B受容体拮抗薬
  • 向け阻害剤 BAX 心筋梗塞向け
  • 向け阻害剤 MMP 心筋梗塞向け
  • 免疫学・腫瘍学・循環器疾患・代謝障害向けPARP阻害剤
  • 循環器疾患向けPDE5阻害剤
  • 酸化的ストレス関連疾患向け遊離基除去小分子
  • 急性心筋梗塞向け幹細胞療法
  • 循環器疾患向け幹細胞療法
  • 循環器疾患・中枢神経障害・代謝障害・呼吸器疾患・炎症性疾患・毒物学向け幹細胞療法
  • 循環器疾患向け幹細胞療法
  • 心筋梗塞・心不全向け幹細胞療法
  • Stempeucel
  • 循環器疾患向けエリスロポエチン(赤血球生成促進因子)受容体活性合成ペプチド
  • TF-0023
  • THR-100
  • ticagrelor
  • TZ-101
  • VN-100
  • ZK-001

心筋梗塞治療薬:パイプライン製品の最新動向

心筋梗塞治療薬:開発が休止状態の製品

心筋梗塞治療薬:開発が中止された製品

心筋梗塞関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9116IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H1 2017, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.

Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 14, 9, 37, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 20 and 7 molecules, respectively.

Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Myocardial Infarction - Overview
  • Myocardial Infarction - Therapeutics Development
  • Myocardial Infarction - Therapeutics Assessment
  • Myocardial Infarction - Companies Involved in Therapeutics Development
  • Myocardial Infarction - Drug Profiles
  • Myocardial Infarction - Dormant Projects
  • Myocardial Infarction - Discontinued Products
  • Myocardial Infarction - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Myocardial Infarction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
  • Myocardial Infarction - Pipeline by AstraZeneca Plc, H1 2017
  • Myocardial Infarction - Pipeline by Athersys Inc, H1 2017
  • Myocardial Infarction - Pipeline by Bayer AG, H1 2017
  • Myocardial Infarction - Pipeline by Bharat Biotech International Ltd, H1 2017
  • Myocardial Infarction - Pipeline by BioCardia Inc, H1 2017
  • Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
  • Myocardial Infarction - Pipeline by Capricor Therapeutics Inc, H1 2017
  • Myocardial Infarction - Pipeline by CellProthera, H1 2017
  • Myocardial Infarction - Pipeline by Chrysalis BioTherapeutics Inc, H1 2017
  • Myocardial Infarction - Pipeline by Compugen Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Cynata Therapeutics Limited, H1 2017
  • Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
  • Myocardial Infarction - Pipeline by FibroGen Inc, H1 2017
  • Myocardial Infarction - Pipeline by Hemostemix Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Human Stem Cells Institute, H1 2017
  • Myocardial Infarction - Pipeline by HUYA Bioscience International LLC, H1 2017
  • Myocardial Infarction - Pipeline by InCarda Therapeutics Inc, H1 2017
  • Myocardial Infarction - Pipeline by Inotrem SA, H1 2017
  • Myocardial Infarction - Pipeline by Juventas Therapeutics Inc, H1 2017
  • Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H1 2017
  • Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
  • Myocardial Infarction - Pipeline by LG Chem, Ltd., H1 2017
  • Myocardial Infarction - Pipeline by Medestea Research & Production SpA, H1 2017
  • Myocardial Infarction - Pipeline by Mesoblast Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Moderna Therapeutics Inc, H1 2017
  • Myocardial Infarction - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
  • Myocardial Infarction - Pipeline by New World Laboratories Inc, H1 2017
  • Myocardial Infarction - Pipeline by Novartis AG, H1 2017
  • Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H1 2017
  • Myocardial Infarction - Pipeline by Omeros Corp, H1 2017
  • Myocardial Infarction - Pipeline by Opsona Therapeutics Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Otsuka Holdings Co Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Pharmahungary Group, H1 2017
  • Myocardial Infarction - Pipeline by Primary Peptides Inc, H1 2017
  • Myocardial Infarction - Pipeline by Quark Pharmaceuticals Inc, H1 2017
  • Myocardial Infarction - Pipeline by Recardio GmbH, H1 2017
  • Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
  • Myocardial Infarction - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Rubicon Biotechnology Inc, H1 2017
  • Myocardial Infarction - Pipeline by Serodus ASA, H1 2017
  • Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals Inc, H1 2017
  • Myocardial Infarction - Pipeline by Stemedica Cell Technologies Inc, H1 2017
  • Myocardial Infarction - Pipeline by TaiGen Biotechnology Co Ltd, H1 2017
  • Myocardial Infarction - Pipeline by Targazyme Inc, H1 2017
  • Myocardial Infarction - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
  • Myocardial Infarction - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2017
  • Myocardial Infarction - Pipeline by TiGenix NV, H1 2017
  • Myocardial Infarction - Pipeline by Vicore Pharma AB, H1 2017
  • Myocardial Infarction - Pipeline by XBiotech Inc, H1 2017
  • Myocardial Infarction - Pipeline by Yuyu Pharma Inc, H1 2017
  • Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Myocardial Infarction - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Myocardial Infarction - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Myocardial Infarction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top